“You know, the model called for second half being higher than first half”

In context

“us. And a lot of that is driven maybe some of that is pricing, some of that is care gap. So my question is, how much visibility do you have on these Caregap programs in the back half stepping up for Exact Sciences? And I think a related question was, the FREE NOM just presented their redo data. Advanced adenoma detection rate was north of 18%. I think that is well above your competition. So when you think about the blood side of you know, CRC screening, do you still expect Abbott to be the market leader on the blood side even though your entry into the market will be slightly behind, Garden. Thank you. Robert Ford: Sure. Yeah. We grew 13%, in the first half. Our deal model, that we put together to support the acquisition, for 2026 had mid-teens. I feel confident that we will achieve that. You know, the model called for second half being higher than first half and the integration is going very good, very well. We are not seeing any kinda issues or disruption. I am I am just very impressed with the team there and their understanding of the market. And they have done a good job here at making sure that I understand all the different, detailed kind of elements of how this market works and drives. To your point of the care gap, care gap volumes ramp in the second half. And that is what is gonna help drive. it is not just that, but it is contributing factor to the acceleration in the second half. Caregap programs really are they help the health systems achieve their HEDIS credit, their CMR star ratings, And that focus from the healthcare systems for some reason, tends to happen in the second half. So they are they are looking at their scores. They a”